Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study

Table 1 Baseline characteristics of the selective serotonin reuptake inhibitor cohort and the non-selective serotonin reuptake inhibitor cohort, 2000-2010 n (%)

Variable	SSRI use		P value
	No (n = 78612)	Yes (n = 19653)
Sex			1.000
Female	45984 (58.5)	11496 (58.5)
Male	32628 (41.5)	8157 (41.5)
Age, yr			1.000
< 20	5548 (7.1)	1387 (7.1)
20-29	11592 (14.8)	2898 (14.8)
30-39	14312 (18.2)	3578 (18.2)
40-49	15112 (19.2)	3778 (19.2)
50-59	11720 (14.9)	2930 (14.9)
≥ 60	20328 (25.9)	5082 (25.9)
Urbanization1			< 0.001
1	24102 (31.3)	6275 (32.7)
2	23134 (30.0)	5851 (30.5)
3	12486 (16.2)	2827 (14.7)
4	17325 (22.5)	4228 (22.0)
Family income (NTD)			< 0.001
0	13932 (17.7)	3411 (17.4)
1-15840	14871 (18.9)	4807 (24.5)
15841-28800	33687 (42.9)	7915 (40.3)
28801-45800	10243 (13.0)	2173 (11.1)
≥ 45801	5874 (7.5)	1346 (6.9)
Area			< 0.001
North	39708 (50.6)	10001 (51.0)
Midland	14067 (17.9)	3265 (16.7)
South	22823 (29.1)	5642 (28.8)
East	1837 (2.3)	690 (3.5)
Occupation			< 0.001
Public and military	5735 (8.2)	1531 (8.8)
Industry	23168 (33.3)	5617 (32.3)
Business	28266 (40.6)	5841 (33.6)
Low income	559 (0.8)	385 (2.2)
Other and retired	11898 (17.1)	3994 (23.0)
Anti-psychotics			< 0.001
No	75615 (96.2)	16022 (81.5)
Yes	2997 (3.8)	3631 (18.5)
Comorbidity
Diabetes mellitus	8126 (10.3)	3143 (16.0)	< 0.001
Hypertension	18319 (23.3)	6726 (34.2)	< 0.001
Hyperlipidemia	11823 (15.0)	4521 (23.0)	< 0.001
Colorectal cancer	290 (0.4)	96 (0.5)	0.017
Major depressive disorder	770 (0.98)	4274 (21.8)	< 0.001
Anxiety disorder	10007 (12.7)	9477 (48.2)	< 0.001
Bipolar disorder	130 (0.2)	273 (1.4)	< 0.001
Posttraumatic stress disorder	7 (0.0)	101 (0.5)	< 0.001
Eating disorder	26 (0.0)	141 (0.7)	< 0.001
Mean follow-up time (yr)	5.86 ± 3.00	5.53 ± 3.21

¹Urbanization level: 1 indicates the highest level of urbanization and 4 the lowest. SSRI: Selective serotonin reuptake inhibitor; NTD: New Taiwan dollars.